Lung cancer marker SBP-1 and its application

Abstract

The invention relates to the molecular biology and tumor medicine fields, and relates to an application of a lung cancer marker SBP-1 in lung cancer diagnosis, and a method for detecting lung cancer by taking SBP-1 as the marker. According to the invention, a comparative proteomics method is employed for comparative analysis of protein expression profile of a lung cancer cell line / tissue and normal control cell / tissue, and a mass spectrum identifies the partial difference protein points. SBP-1 protein is a difference point, and enables high expression in cancer cells by comparing with that of the normal cells, and the difference is obvious. The invention employs RT-PCR and an immunohistochemical technology to respectively detect mRNA of SBP-1 and expression level of protein expression in normal tissue, the result displays that the expression of SBP-1 in the lung cancer tissue is obviously higher than that of its paired normal tissue, so that SBP-1 can be taken as a diagnosis marker of lung cancer. The invention also provides a lung cancer diagnostic kit and a detection method used for lung cancer.

Description

technical field [0001] The invention relates to the fields of molecular biology and tumor medicine. Specifically, the present invention relates to the use of a lung cancer marker SBP-1 in the diagnosis of lung cancer, and a method for detecting lung cancer using SBP-1 as a marker. Background technique [0002] Studies have reported that lung cancer is currently one of the most common malignant tumors, and it is also the tumor with the fastest increasing morbidity and mortality worldwide. According to statistics, about 1.2 million patients are diagnosed with lung cancer each year, and 1.1 million people die of lung cancer. Lung cancer can be divided into two categories based on its histopathology: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. [0003] To date, lung cancer screening programs around the world are immature. Therefore, early screening and diagnosis ...

AI Technical Summary

Problems solved by technology

[0005] So far, there are no clinically applicable detection reagents for effective early screening and diagnosis of lung cancer, especially the detection reagents and methods for lung cancer with SBP-1 as a marker, which will provide in-depth research and large-scale verification The correlation between SBP-1 and lung cancer is of great significance for the diagnosis of cancer and the provision of adjuvant therapy for individual patients